Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model

• Published in: Theranostics Vol. 11; no. 17; pp. 8129 - 8142
• Main Authors: Cone, Allaura S, Yuan, Xuegang, Sun, Li, Duke, Leanne C, Vreones, Michael P, Carrier, Allison N, Kenyon, Stephanie M, Carver, Spencer R, Benthem, Sarah D, Stimmell, Alina C, Moseley, Shawn C, Hike, David, Grant, Samuel C, Wilber, Aaron A, Olcese, James M, Meckes, Jr, David G
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2021; Ivyspring International Publisher
• Subjects: Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Animals; Apoptosis; Bone marrow; Brain - metabolism; Disease Models, Animal; Extracellular vesicles; Extracellular Vesicles - metabolism; Hippocampus - metabolism; Homeostasis; Hypotheses; Immunomodulation; Inflammation; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells - metabolism; Mice; Mice, Transgenic; Microscopy; Mutation; Plaque, Amyloid - metabolism; Polyethylene glycol; Proteins; Research Paper; Stem cells; extracellular vesicles; microvesicles; Alzheimer's disease; exosomes; mesenchymal stem cells
• ISSN: 1838-7640
• DOI: 10.7150/thno.62069

Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that affects more than 44 million people worldwide. Despite the high disease burden, there is no effective treatment for people suffering from AD. Mesenchymal stem cells (MSCs) are multipotent stromal cells that have been widely studied due to their therapeutic potential. However, administration of cells has been found to have a multitude of limitations. Recently, extracellular vesicles (EVs) derived from MSCs have been studied as a therapeutic candidate, as they exhibit similar immunoprotective and immunomodulatory abilities as the host human MSCs. To test the potential therapeutic effects of MSC EVs, human bone-marrow derived MSCs were grown in three-dimensional (3D) cell culture, and small EVs were harvested using differential ultracentrifugation. These small EVs were given to non-transgenic (NT) or 5XFAD (5 familial Alzheimer's disease mutations) mice intranasally (IN) every 4 days for 4 months. The mice were then required to perform a variety of behavioral assays to measure changes in learning and memory. Afterwards, immunohistochemistry was performed on brain slices to measure amyloid beta (Aβ) and glial fibrillary acidic protein (GFAP) levels. The data revealed that 5XFAD mice that received hMSC-EV treatment behaved significantly better in cognitive tests than saline treated 5XFAD mice, with no significant change between EV-treated 5XFAD mice and NT mice. Additionally, we found lower Aβ plaque load in the hippocampus of the EV-treated mice. Finally, less colocalization between GFAP and Aβ plaques was found in the brain of EV-treated mice compared to saline. Taken together, these data suggest that IN administration of MSC-derived EVs can slow down AD pathogenesis.